Stockreport

Alumis Spotlights Phase III Psoriasis Data for Envudeucitinib, Teases NDA and Lupus Readout [Yahoo! Finance]

Alumis Inc.  (ALMS) 
PDF 16 and roughly ~40% PASI100 at week 24 — with rapid onset and marked itch and DLQI improvements. Safety/tolerability through 24 weeks was favorable, with the most comm [Read more]